154 related articles for article (PubMed ID: 25452864)
1. Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials.
Davidson JA; Lajara R; Aguilar RB; Mattheus M; Woerle HJ; von Eynatten M
BMJ Open Diabetes Res Care; 2014; 2(1):e000020. PubMed ID: 25452864
[TBL] [Abstract][Full Text] [Related]
2. Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
Lehrke M; Marx N; Patel S; Seck T; Crowe S; Cheng K; von Eynatten M; Johansen OE
Clin Ther; 2014 Aug; 36(8):1130-46. PubMed ID: 25015594
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial.
Chen Y; Ning G; Wang C; Gong Y; Patel S; Zhang C; Izumoto T; Woerle HJ; Wang W
J Diabetes Investig; 2015 Nov; 6(6):692-8. PubMed ID: 26543544
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.
Thrasher J; Kountz DS; Crowe S; Woerle HJ; von Eynatten M
Postgrad Med; 2015 Jun; 127(5):419-28. PubMed ID: 25840727
[TBL] [Abstract][Full Text] [Related]
5. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.
Schernthaner G; Barnett AH; Emser A; Patel S; Troost J; Woerle HJ; von Eynatten M
Diabetes Obes Metab; 2012 May; 14(5):470-8. PubMed ID: 22268497
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis.
Zeng Z; Choi DS; Mohan V; Emser A; Siddiqui K; Gong Y; Patel S; Woerle HJ
Curr Med Res Opin; 2015 Jan; 31(1):99-106. PubMed ID: 25215428
[TBL] [Abstract][Full Text] [Related]
8. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
[TBL] [Abstract][Full Text] [Related]
9. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials.
Kanasaki K; Qu S; Yamamoto F; Schepers C; Sani Simões R; Yabe D; Ji L
Expert Opin Drug Saf; 2022 Mar; 21(3):425-434. PubMed ID: 34711126
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
12. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials.
Lehrke M; Leiter LA; Hehnke U; Thiemann S; Bhandari A; Meinicke T; Johansen OE
J Diabetes Complications; 2016; 30(7):1378-84. PubMed ID: 27396241
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials.
Raji A; Long J; Lam RLH; O'Neill EA; Engel SS
Diabetes Ther; 2018 Aug; 9(4):1581-1589. PubMed ID: 29936573
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
Zeng Z; Yang JK; Tong N; Yan S; Zhang X; Gong Y; Woerle HJ
Curr Med Res Opin; 2013 Aug; 29(8):921-9. PubMed ID: 23672632
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
Usiskin K; Kline I; Fung A; Mayer C; Meininger G
Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension.
Gomis R; Owens DR; Taskinen MR; Del Prato S; Patel S; Pivovarova A; Schlosser A; Woerle HJ
Int J Clin Pract; 2012 Aug; 66(8):731-740. PubMed ID: 22691164
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials.
von Eynatten M; Gong Y; Emser A; Woerle HJ
Cardiovasc Diabetol; 2013 Apr; 12():60. PubMed ID: 23570327
[TBL] [Abstract][Full Text] [Related]
19. Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial.
Ma RC; Del Prato S; Gallwitz B; Shivane VK; Lewis-D'Agostino D; Bailes Z; Patel S; Lee J; von Eynatten M; Di Domenico M; Ross SA
J Diabetes Investig; 2017 Sep; 9(3):579-86. PubMed ID: 28921919
[TBL] [Abstract][Full Text] [Related]
20. The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetes.
Heise T; Larbig M; Patel S; Seck T; Hehnke U; Woerle HJ; Dugi K
Diabetes Obes Metab; 2014 Oct; 16(10):1036-9. PubMed ID: 24821586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
